osimertinib and honokiol

osimertinib has been researched along with honokiol* in 1 studies

Other Studies

1 other study(ies) available for osimertinib and honokiol

ArticleYear
Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.
    Molecular oncology, 2020, Volume: 14, Issue:4

    The development of acquired resistance to osimertinib (Osim) (AZD9291 or TAGRISSO

    Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lignans; Lung Neoplasms; Mice, Nude; Mutation; Protein Kinase Inhibitors

2020